PriceTargets.com logo

Citius Pharmaceuticals - CTXR Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.03 As of 03/24/2023 01:00 AM ET
▲ +0.03 (3.00%)

This chart shows the closing price for CTXR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Citius Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTXR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTXR

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.03.

This chart shows the closing price for CTXR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Citius Pharmaceuticals. This rating has held steady since January 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/11/2022Maxim GroupInitiated CoverageBuy$4.00Medium
1/18/2022HC WainwrightBoost TargetBuy$4.00 ➝ $6.00Medium
11/30/2021Maxim GroupInitiated CoverageBuy$4.00Medium
3/1/2021HC WainwrightReiterated RatingBuyLow
2/25/2021Dawson JamesReiterated RatingBuy$6.00Low
9/17/2020Dawson JamesReiterated RatingBuyLow
8/18/2020HC WainwrightReiterated RatingBuy$4.00Low
5/19/2020HC WainwrightReiterated RatingBuy$4.00High
1/24/2020HC WainwrightReiterated RatingBuy$4.00High
9/6/2019Dawson JamesInitiated CoverageBuy$7.00N/A
2/7/2019HC WainwrightReiterated RatingBuy$3.00High
5/23/2018HC WainwrightInitiated CoverageBuy$11.00High
(Data available from 3/26/2018 forward)

News Sentiment Rating

1.04 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/25/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Citius Pharmaceuticals logo
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
Read More

Today's Range

Now: $1.03
Low: $0.97
High: $1.03

50 Day Range

MA: $1.20
Low: $0.98
High: $1.42

52 Week Range

Now: $1.03
Low: $0.77
High: $2.01

Volume

333,324 shs

Average Volume

619,594 shs

Market Capitalization

$150.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Citius Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Citius Pharmaceuticals in the last year:
View the latest analyst ratings for CTXR.

What is the current price target for Citius Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Citius Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Citius Pharmaceuticals in the next year.
View the latest price targets for CTXR.

What is the current consensus analyst rating for Citius Pharmaceuticals?

Citius Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CTXR.

What other companies compete with Citius Pharmaceuticals?

Other companies that are similar to Citius Pharmaceuticals include Cue Biopharma, G1 Therapeutics, Spectrum Pharmaceuticals, Nektar Therapeutics and Olema Pharmaceuticals. Learn More about companies similar to Citius Pharmaceuticals.

How do I contact Citius Pharmaceuticals' investor relations team?

Citius Pharmaceuticals' physical mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company's listed phone number is (908) 967-6677 and its investor relations email address is [email protected] The official website for Citius Pharmaceuticals is www.citiuspharma.com. Learn More about contacing Citius Pharmaceuticals investor relations.